HPLC-DAD-ELSD法同时测定复方贞术调脂胶囊15个活性成分

doi:10.5246/jcps.2013.01.006

HPLC-DAD-ELSD法同时测定复方贞术调脂胶囊15个活性成分

范辉, 郭姣^*, 陈媛媛

1. 国家中医药管理局“高脂血症调肝降脂重点研究室”、“脂代谢三级实验室”、广东省“代谢性疾病中医药防治重点实验室”、广东药学院中医药研究院, 广东广州 510006
2. 广东药学院药科学院, 广东广州 510006

收稿日期:2012-10-05 修回日期:2012-12-20 出版日期:2013-01-20 发布日期:2013-01-20

Simultaneous determination of 15 bioactive compounds in Fufang Zhenzhu Tiaozhi capsules by HPLC-DAD-ELSD

Hui Fan, Jiao Guo^*, Yuanyuan Chen

1. Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangdong TCM Key Laboratory for Metabolic Diseases, Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Centre, Guangzhou 510006, China
2. College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China

Received:2012-10-05 Revised:2012-12-20 Online:2013-01-20 Published:2013-01-20
Contact: Jiao Guo*

摘要/Abstract

摘要：

复方贞术调脂胶囊 (FTZc) 是一种用于治疗高脂血症的专利药物, 由八味中药组成, 含有多活性成分的复方制剂。本文建立了可行的HPLC-DAD-ELSD方法用于FTZc的质量控制, 同时测定15个活性成分 (红景天苷、特女贞苷、木兰碱、迷迭香酸、丹酚酸B、非洲防己碱、表小檗碱、药根碱、黄连碱、巴马汀、小檗碱、5,7-二甲氧基香豆素、人参皂苷Rg1、人参皂苷Rb1和齐墩果酸)。色谱柱采用Ultimate XB C18, 流动相为乙腈-水 (0.25%乙酸, 0.13%三乙胺) (梯度洗脱), 流速为0.8 mL/min, 检测方法采用光电二极管阵列检测器的多波长检测模式和蒸发光散射检测器联合应用。方法学验证表明该方法精密度、准确度良好, 成功用于不同批次FTZc的测定。结果表明, 本文建立的测定多种生物活性成分HPLC-DAD-ELSD方法切实可行、方法可靠, 特别适用于复方贞术调脂胶囊的质量评价。

关键词: HPLC-DAD-ELSD, 复方贞术调脂胶囊, 质量控制

Abstract:

Fufang Zhenzhu Tiaozhi capsules (FTZc), which is consisted of eight traditional Chinese herbal medicines and contains multiple bioactive ingredients, is a patented and clinically approved herbal formulation for the treatment of dyslipidemia. A feasible HPLC-DAD-ELSD method was developed to simultaneously determine 15 bioactive compounds (salidroside, specneuzhenide, magnoflorine, rosmarinic acid, salvianolic acid B, columbamine, jatrorrhizine, epiberberine, coptisine, palmatine, berberine, 5,7-dimethoxycoumarin, ginsenoside Rg1, ginsenoside Rb1 and oleanic acid ) in FTZc for its quality control. The multiple wavelength detection mode of DAD was used. The chromatographic separation was performed on an Ultimate XB C18 column with gradient elution. The mobile phase A (acetonitrile) and B (0.25% glacial acetic acid and 0.13% triethylamine in water, v/v) were run at a flow rate of 0.8 mL/min. The developed method showed good precision and accuracy with overall intra- and inter-day variations of 0.7%-1.9% and 0.6%-3.0%, respectively. The recoveries measured at three concentration levels, varied from 95.5% to 103.8%. The validated method was successfully applied for the simultaneous determination of 15 bioactive compounds in three batches of FTZc. The results suggested that the developed method was convenient and reliable, particularly suitable for the routine quality control of FTZc.

Key words: HPLC-DAD-ELSD, Fufang Zhenzhu Tiaozhi capsule, Quality control

中图分类号:

R284.1

Supporting:

Foundation items: Guangdong Administration of Traditional Chinese Medicine Research Projects China (Grant No. 2010200), a cooperation Project in Industry, Education and Research of Guangdong Province and Ministry of Education of China (Grant No. 2009B090300349) and a cooperation project of National Science Foundation of Guangdong Province (Grant No. 10351022401000000), a Guangzhou City Science and Technology Support Program (Grant No. 2009Z1-E361).
^*Corresponding author. Tel.: 020-39352609

范辉, 郭姣^*, 陈媛媛. HPLC-DAD-ELSD法同时测定复方贞术调脂胶囊15个活性成分[J]. , DOI: 10.5246/jcps.2013.01.006.

Hui Fan, Jiao Guo^*, Yuanyuan Chen. Simultaneous determination of 15 bioactive compounds in Fufang Zhenzhu Tiaozhi capsules by HPLC-DAD-ELSD[J]. , DOI: 10.5246/jcps.2013.01.006.

参考文献

[1] Guo, J. China Patent. 200410051250. June, 2005.

[2] Guo, J.; Bei, W.J.; Hu, Y.M.; Tang, C.P.; He, W.; Liu, X.B.; Huang, L.H.; Cao, Y.; Hu, X.G.; Zhong, X.L; Cao, L. J. Ethnopharmacol. 2011, 135, 299-307.

[3] Tang, F.T.; Guo, J.; He, W.; Wang, L.J.; Luo, D.S.; Bei, W.J. Chin. J. Integr. Med. 2011. Doi: 10.1007/S11655-011-0794-Z

[4] Wei, Y.J.; Qi, L.W.; Li, P.; Luo, H.W.; Yi, L.; Sheng, L.H. J. Pharm. Biomed. Anal. 2007, 45, 775-784.

[5] Zhong, X.L.; Guo, J.; Wang, L.Y.; Luo, D.S.; Bei, W.J.; Chen, Y.Y.; Yan, K.Q.; Peng, J.H. Chromatographia. 2012, 75, 111-129.

[6] Xia, W.; Sun, C.; Zhao, Y.; Wu, L. Phytomedicine. 2011, 18, 516-520.

[7] Wang, J.; Hu, J.H. China. J. China Mater. Med. 2006, 31, 588-590.

[8] Yokozawa, T.; Ishida, A.; Cho, E.J.; Nakagawa, T. Phytomedicine. 2003, 10, 17-22.

[9] Kong, W.J.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.L.; Wang, Z.Z.; Si, S.Y.; Pan, H.N.; Wang, S.K.; Wu, J.D.; Wang, Y.; Li, Z.R.; Liu, J.W.; Jiang, J.D. Nat. Med. 2004, 10, 1344-1351.

[10] Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; Wang, S.; Wu, J.; Wang, Y.; Li, Z.; Liu, J.; Jiang, J.D. Eur. J. Pharmacol. 2011, 668, 467-471.

[11] Hung, T.M.; Lee, J.P.; Min, B.S.; Choi, J.S.; Na, M.; Zhang, X.; Ngoc, T.M.; Lee, I.; Bae, K. Biol. Pharm. Bull. 2007, 30, 1157-1160.

[12] Zhang, X.M.; Qu, S.C.; Sui, D.Y.; Yu, X.F.; Lv, Z.Z. China J. Chin. Mater. Med. 2004, 29, 1085-1088.

[13] Fadel, O.; El Kirat, K.; Morandat, S. Biochim. Biophys. Acta. 2011, 1808, 2973-2980.

[14] Yang, T.L.; Lin, F.Y.; Chen, Y.H.; Chiu, J.J.; Shiao, M.S.; Tsai, C.S.; Lin, S.J.; Chen, Y.L. J. Sci. Food. Agric. 2011, 91, 134-141.

[15] Buus, N.H.; Hansson, N.C.; Rodriguez-Rodriguez, R.; Stankevicius, E.; Andersen, M.R.; Simonsen, U. Eur. J. Pharmacol. 2011, 670, 519-526.

[16] Yao, X.; He, W.; Li, Y.; Yong, L.I.; Ma, J.C.; Yan, X.H. J. China. Pharm. 2011, 22, 1398-1400.

[17] Chen, Y.Y.; Guo, J.; Fan, H.; Huan, L.H. Chin. Herb. Med. 2012, 4, 230-236

[18] Wang, H.L.; Yao, W.F.; Zhu, D.N.; He, Y.Z. Chin. J. Nat. Med. 2011, 8, 343-348.

[19] Ye, J.; Zhang, X.; Dai, W.; Yan, S.; Huang, H.; Liang, X.; Li, Y.; Zhang, W. J. Pharm. Biomed. Anal. 2009, 49, 638-645.